| Business Summary | | Accredo
Health,
Incorporated
provides
specialized
contract
pharmacy
and
related
services
pursuant
to
agreements
with
biotechnology
drug
manufacturers
relating
to
the
treatment
of
patients
with
certain
costly
chronic
diseases.
The
Company
addresses
the
needs
of
the
manufacturers
by
providing
specialized
services
that
facilitate
product
launch
and
patient
acceptance
including
the
collection
of
timely
drug
utilization
and
patient
compliance
information,
patient
education
and
monitoring
through
the
use
of
written
materials
and
telephonic
consultation,
reimbursement
expertise
and
overnight
drug
delivery.
The
Company
has
designed
its
specialty
services
to
focus
primarily
on
biotechnology
drugs
that
are
used
on
a
recurring
basis
to
treat
chronic,
and
potentially
life
threatening
diseases,
are
expensive,
are
administered
through
injection,
and
require
temperature
control
or
other
specialized
handling
as
part
of
their
distribution
process. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Accredo
Health,
Inc.
provides
specialized
contract
pharmacy
and
related
services
pursuant
to
agreements
with
biotechnology
drug
manufacturers
relating
to
the
treatment
of
patients
with
certain
costly,
chronic
diseases.
For
the
fiscal
year
ended
6/30/01,
revenues
increased
31%
to
$462.1
million.
Net
Income
increased
74%
to
$17.3
million.
Results
reflect
growth
in
seasonal
SYNAGIS
drug
sales
and
the
acquisition
of
Pharmcare
Resources,
and
the
reduction
of
bad
debt
cost. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Stevens, 47 Chairman
and CEO | $504K | $2.5M | John Grow, 52 Pres | 290K | 2.6M | Joel Kimbrough, 42 CFO,
Sr. VP, Treasurer | 285K | 1.1M | Kyle Callahan, 34 Sr.
VP | 278K | -- | Thomas Bell, Jr., 49 Sr.
VP, Gen. Counsel and Sec. | 271K | 2.5M | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|